(Q43040677)

English

Treatment of chronic hepatitis C genotype 1 patients at an academic center in Europe involved in prospective, controlled trials: is there a selection bias?

scientific article published on 30 November 2011

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Treatment of chronic hepatitis C genotype 1 patients at an academic center in Europe involved in prospective, controlled trials: is there a selection bias? (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

1 reference

based on heuristic

inferred from title

chronic hepatitis C

1 reference

based on heuristic

inferred from title

author name string

Sandra Beinhardt

1

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Albert F Staettermayer

2

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Karoline Rutter

3

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Judith Maresch

4

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Thomas M Scherzer

5

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Petra Steindl-Munda

6

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Harald Hofer

7

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Peter Ferenci

8

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

language of work or name

0 references

publication date

30 November 2011

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

55

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

30-38

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24671

21 January 2018

Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24671

21 January 2018

Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24671

21 January 2018

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24671

21 January 2018

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24671

21 January 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24671

21 January 2018

Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24671

21 January 2018

The hepatitis C virus life cycle as a target for new antiviral therapies

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24671

21 January 2018

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24671

21 January 2018

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24671

21 January 2018

Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24671

21 January 2018

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24671

21 January 2018

Telaprevir for previously untreated chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24671

21 January 2018

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24671

21 January 2018

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24671

21 January 2018

Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24671

21 January 2018

Hepatitis C pharmacogenetics: state of the art in 2010.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24671

21 January 2018

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24671

21 January 2018

A proposed method to adjust for selection bias in cohort studies.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24671

21 January 2018

A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24671

21 January 2018

The presence of steatosis and elevation of alanine aminotransferase levels are associated with fibrosis progression in chronic hepatitis C with non-response to interferon therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24671

21 January 2018

High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24671

21 January 2018

Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24671

21 January 2018

Racial differences in hepatitis C treatment eligibility

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24671

21 January 2018

Insurance status and treatment candidacy of hepatitis C patients: analysis of population-based data from the United States

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24671

21 January 2018

Adherence to Medication

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24671

21 January 2018

A systematic review of the associations between dose regimens and medication compliance

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24671

21 January 2018

Distributive justice and the arrival of direct-acting antivirals: who should be first in line?

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24671

21 January 2018

Outcomes of treatment for hepatitis C virus infection by primary care providers

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24671

21 January 2018

A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24671

21 January 2018

Standard interferon-alpha in combination with ribavirin for hepatitis C patients with advanced liver disease and thrombocytopenia

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24671

21 January 2018

Insurance status and treatment candidacy of patients with hepatitis C: Taiwanese patients are luckier

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24671

21 January 2018

Identifiers

10.1002/HEP.24671

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43040677&oldid=1590219679"